Pancreatic Cancer Research

ResearcherLeidos Biomedical Research Inc. (United States)Active in the last 2 years

Gloria M. Petersen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3424-7039; OpenAlex author ID A5048782070; NIH RePORTER profile ID 1894106. Sources: ClinicalTrials.gov.

Their work

Papers
139 (first author 4, last author 26)
Trials
2 (principal investigator on 2)
Grants
7
Labs led
1
Collaborators
365
Papers, trials and grants by year

2011: 9 papers · 2012: 13 papers, 1 grant · 2013: 13 papers, 1 trial · 2014: 12 papers · 2015: 16 papers, 1 trial, 1 grant · 2016: 13 papers · 2017: 10 papers, 1 grant · 2018: 13 papers, 1 grant · 2019: 8 papers · 2020: 12 papers, 1 grant · 2021: 11 papers · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 2 grants

Papers 50 of 139

  1. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  2. Polycyclic Aromatic Hydrocarbons and Pancreatic Cancer: An Analysis of the Blood Biomarker, r-1,t-2,3,c-4-Tetrahydroxy-1,2,3,4-tetrahydrophenanthrene and Selec… Co-author DOI 10.3390/nu16050688↗
  3. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germlin… Co-author DOI 10.1001/jamaoncol.2023.0806↗
  4. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Co-author DOI 10.1016/j.cca.2023.117567↗
  5. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  6. Pancreatic cancer risk to siblings of probands in bilineal cancer settings. Last author DOI 10.1016/j.gim.2022.01.016↗
  7. Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.06.259↗
  8. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives. Last author DOI 10.1158/1055-9965.epi-21-0745↗
  9. A Pilot Study of Blood-Based Methylation Markers Associated With Pancreatic Cancer. Last author DOI 10.3389/fgene.2022.849839↗
  10. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. Co-author DOI 10.1001/jamaoncol.2021.3701↗
  11. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  12. A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. Co-author DOI 10.1016/j.jbc.2021.100634↗
  13. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Co-author DOI 10.1038/s41416-021-01580-x↗
  14. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  15. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  16. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1055-9965.epi-20-1279↗
  17. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. Co-author DOI 10.1158/1078-0432.ccr-20-0235↗
  18. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. Co-author DOI 10.1158/1940-6207.capr-20-0403↗
  19. Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Co-author DOI 10.1158/1940-6207.capr-20-0642↗
  20. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  21. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  22. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  23. Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4). Co-author DOI 10.1097/cej.0000000000000572↗
  24. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  25. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  26. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. Last author DOI 10.1158/1055-9965.epi-19-1597↗
  27. Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0091↗
  28. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  29. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  30. Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1788↗
  31. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  32. Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients. Co-author DOI 10.3390/cancers12061534↗
  33. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Co-author DOI 10.1016/j.ccell.2018.12.010↗
  34. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. Co-author DOI 10.1038/s41436-019-0517-y↗
  35. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status. Last author DOI 10.1093/jnci/djx272↗
  36. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  37. Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. Co-author DOI 10.1158/1055-9965.epi-18-1235↗
  38. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  39. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Co-author DOI 10.1200/jco.18.01489↗
  40. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. Co-author DOI 10.1371/journal.pgen.1008344↗
  41. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. Co-author DOI 10.1001/jama.2018.6228↗
  42. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Co-author DOI 10.1007/s10689-017-0019-5↗
  43. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-018-3695-z↗
  44. Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Last author DOI 10.1038/gim.2017.85↗
  45. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  46. Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Co-author DOI 10.1053/j.gastro.2018.05.023↗
  47. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  48. Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. Last author DOI 10.1093/carcin/bgy072↗
  49. Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review. First author DOI 10.1097/mpa.0000000000000995↗
  50. Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001165↗

Trials 2

  1. Understanding Genetic Incidental Findings in Your Family (UNIFY Study) Principal investigator NCT02560896↗
  2. Examination of the Pancreas in New-onset Diabetes Principal investigator NCT02001337↗

Grants 7

  1. Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer U01CA210138↗
  2. The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer U01DK108288↗
  3. Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds R01CA208517↗
  4. Administrative Core P50CA102701↗
  5. Validation and Temporal Performance of Pancreatic Cancer Biomarkers in Prospective Cohorts AWARD pancan:2017-gloria-petersen-validation-and-temporal-performance-of-p
  6. Disclosing Genomic Incidental Findings in a Cancer Biobank: An ELSI Experiment R01CA154517↗
  7. Pancreatic Cancer Genetic Epidemiology Consortium (PACGENE) R01CA097075↗

Closest collaborators

The 25 strongest of 365 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kari G. Rabe · 38 shared papers, 2011–2023 · strength 2.63
  2. Suresh T. Chari · 19 shared papers, 2 shared grants, 2012–2026 · strength 2.28
  3. Ann L. Oberg · 25 shared papers, 2011–2024 · strength 1.79
  4. Shounak Majumder · 5 shared papers, 1 shared grant, 2020–2026 · strength 1.68
  5. Steve Gallinger · 27 shared papers, 2011–2022 · strength 1.24
  6. Robert R. McWilliams · 18 shared papers, 2011–2022 · strength 1.15
  7. Samuel O. Antwi · 12 shared papers, 2015–2022 · strength 1.11
  8. Alison P. Klein · 16 shared papers, 2012–2024 · strength 1.08
  9. Kenneth Zaret · 1 shared grant, 2026 · strength 1.00
  10. Michael Goggins · 14 shared papers, 2012–2024 · strength 1.00
  11. Mark D. Topazian · 1 shared paper, 1 shared grant, 2020–2026 · strength 0.94
  12. Santhi Swaroop Vege · 1 shared paper, 1 shared grant, 2020–2026 · strength 0.94
  13. Sapna Syngal · 12 shared papers, 2012–2024 · strength 0.85
  14. Rick J. Jansen · 10 shared papers, 2011–2024 · strength 0.81
  15. Martín E. Fernández-Zapico · 4 shared papers, 2 shared grants, 2012–2021 · strength 0.76
  16. Fergus Joseph Couch · 6 shared papers, 1 shared grant, 2016–2022 · strength 0.73
  17. Rachael Z. Stolzenberg‐Solomon · 14 shared papers, 2011–2022 · strength 0.63
  18. Harvey A. Risch · 14 shared papers, 2011–2022 · strength 0.59
  19. Paige M. Bracci · 15 shared papers, 2011–2022 · strength 0.59
  20. Sara H. Olson · 14 shared papers, 2011–2020 · strength 0.54
  21. Anirban Maitra · 5 shared papers, 2015–2024 · strength 0.54
  22. Ayelet Borgida · 9 shared papers, 2012–2021 · strength 0.53
  23. Aminah Jatoi · 5 shared papers, 2017–2021 · strength 0.51
  24. Shruti Chandra · 3 shared papers, 2022–2023 · strength 0.50
  25. Lisa A. Boardman · 6 shared papers, 2012–2021 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.